Opportunities and challenges following approval of resmetirom for MASH liver disease

Jeffrey V. Lazarus; Dana Ivancovsky Wajcman; Henry E. Mark; Zobair M.  Younossi; Christopher J.  Kopka; Nevin Cohen; Meena B. Bansal; Michael Betel; Paul N. Brennan

doi:10.1038/s41591-024-02958-z

Opportunities and challenges following approval of resmetirom for MASH liver disease

Jeffrey V. Lazarus (Lead / Corresponding author)
, Dana Ivancovsky Wajcman
, Henry E. Mark
, Zobair M. Younossi
, Christopher J. Kopka
, Nevin Cohen
, Meena B. Bansal
, Michael Betel
, Paul N. Brennan

Research output: Contribution to journal › Comment/debate

52 Citations (Scopus)

103 Downloads (Pure)

Abstract

The US Food and Drug Administration (FDA) has approved the first drug, resmetirom, for metabolic dysfunction-associated steatohepatitis (MASH), but much work remains for the industry, practitioners and health systems so that this approval will benefit all patients.

Original language	English
Number of pages	4
Journal	Nature Medicine
Early online date	19 Apr 2024
DOIs	https://doi.org/10.1038/s41591-024-02958-z
Publication status	E-pub ahead of print - 19 Apr 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Drug regulation
Health policy
Non-alcoholic fatty liver disease
Non-alcoholic steatohepatitis
Public health

ASJC Scopus subject areas

General Biochemistry,Genetics and Molecular Biology

Access to Document

10.1038/s41591-024-02958-z

Author Accepted ManuscriptAccepted author manuscript, 254 KB

Cite this

@article{79dac870334e4767b07b8ee1c95a9e0b,

title = "Opportunities and challenges following approval of resmetirom for MASH liver disease",

abstract = "The US Food and Drug Administration (FDA) has approved the first drug, resmetirom, for metabolic dysfunction-associated steatohepatitis (MASH), but much work remains for the industry, practitioners and health systems so that this approval will benefit all patients.",

keywords = "Drug regulation, Health policy, Non-alcoholic fatty liver disease, Non-alcoholic steatohepatitis, Public health",

author = "Lazarus, \{Jeffrey V.\} and Wajcman, \{Dana Ivancovsky\} and Mark, \{Henry E.\} and Younossi, \{Zobair M.\} and Kopka, \{Christopher J.\} and Nevin Cohen and Bansal, \{Meena B.\} and Michael Betel and Brennan, \{Paul N.\}",

note = "Publisher Copyright: {\textcopyright} Springer Nature America, Inc. 2024.",

year = "2024",

month = apr,

day = "19",

doi = "10.1038/s41591-024-02958-z",

language = "English",

journal = "Nature Medicine",

issn = "1078-8956",

publisher = "Nature Research",

}

TY - JOUR

T1 - Opportunities and challenges following approval of resmetirom for MASH liver disease

AU - Lazarus, Jeffrey V.

AU - Wajcman, Dana Ivancovsky

AU - Mark, Henry E.

AU - Younossi, Zobair M.

AU - Kopka, Christopher J.

AU - Cohen, Nevin

AU - Bansal, Meena B.

AU - Betel, Michael

AU - Brennan, Paul N.

PY - 2024/4/19

Y1 - 2024/4/19

N2 - The US Food and Drug Administration (FDA) has approved the first drug, resmetirom, for metabolic dysfunction-associated steatohepatitis (MASH), but much work remains for the industry, practitioners and health systems so that this approval will benefit all patients.

AB - The US Food and Drug Administration (FDA) has approved the first drug, resmetirom, for metabolic dysfunction-associated steatohepatitis (MASH), but much work remains for the industry, practitioners and health systems so that this approval will benefit all patients.

KW - Drug regulation

KW - Health policy

KW - Non-alcoholic fatty liver disease

KW - Non-alcoholic steatohepatitis

KW - Public health

UR - https://www.scopus.com/pages/publications/85191061514

U2 - 10.1038/s41591-024-02958-z

DO - 10.1038/s41591-024-02958-z

M3 - Comment/debate

C2 - 38641752

SN - 1078-8956

JO - Nature Medicine

JF - Nature Medicine

ER -

Opportunities and challenges following approval of resmetirom for MASH liver disease

Abstract

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this